REFERENCES
- Fiehn C, Hajjar Y, Mueller K, et al. Improved clinical out-come of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis. 2003; 62: 435–439
- Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM. 1999; 92: 211–218
- Uramoto KM, Michet CJ, Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum. 1999; 42: 46–50
- Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006; 70: 732–742
- Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47: 85–118
- Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991; 33: 161–173
- Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant. 1999; 14: 58–63
- Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 2000; 58: 51–61
- Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999; 31: 1250–1252
- Heemann U, Azuma H, Schmid C, et al. Effects of mycophenolic acid mofetil on acute rejection of kidney allografts in rats. Clin Nephrol. 1996; 45: 355–357
- Lui SL, Tsang R, Wong D, et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/Lpr mice. Lupus. 2002; 11: 411–418
- Ponticelli C, Moroni G. Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus. 1998; 7: 635–638
- El Hachmi M, Jadoul M, Lefebvre C, et al. Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus. 2003; 12: 692–696
- Moroni G, Quaglini S, Maccario M, et al. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996; 50: 2047–2053
- Gourley MF, Austin HA, III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial. Ann Intern Med. 1996; 125: 549–557
- Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001; 135: 248–257
- Boumpas DT, Austin HA, III, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993; 119: 366–369
- Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998; 41: 831–837
- Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum. 1995; 38: 1120–1127
- Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000; 35: 904–914
- Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46: 2121–2131
- Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350: 971–980